Jacobson Mark L. insider trades
Jacobson Mark L. has filed 17 Form 4s with the SEC that we hold, all for Axsome Therapeutics, Inc. (AXSM), as Chief Operating Officer. Across all of them we count 0 purchases worth $0 and 13 sales worth $28.8M reported on Form 4. In the last 12 months: 0 purchases ($0) and 4 sales ($8.9M). The largest single trade was a sale of 35,378 shares of Axsome Therapeutics, Inc. worth $5.7M, dated 2026-02-26. Of 1 sale filed since we began reading the 10b5-1 checkbox, 1 (100%) was marked as made under a 10b5-1 trading plan. The first filing on our record is dated 2021-11-15 and the latest 2026-09-03.
Axsome Therapeutics, Inc. (AXSM)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2024-04-01 | S, sale reported on Form 4 | 24,662 | $1.9M | 2024-04-01 |
| 2024-05-29 | S, sale reported on Form 4 | 7,910 | $587.8K | 2024-05-29 |
| 2024-08-09 | S, sale reported on Form 4 | 47,739 | $4.0M | 2024-08-09 |
| 2025-05-27 | S, sale reported on Form 4 | 20,673 | $2.2M | 2025-05-28 |
| 2025-05-28 | S, sale reported on Form 4 | 20,000 | $2.1M | 2025-05-28 |
| 2025-06-09 | S, sale reported on Form 4 | 25,000 | $2.8M | 2025-06-10 |
| 2025-09-16 | S, sale reported on Form 4 | 5,783 | $671.9K | 2025-09-17 |
| 2025-09-16 | S, sale reported on Form 4 | 40,000 | $4.6M | 2025-09-17 |
| 2025-09-22 | S, sale reported on Form 4 | 10,000 | $1.2M | 2025-09-22 |
| 2026-02-26 | S, sale reported on Form 4 | 35,378 | $5.7M | 2026-02-27 |
| 2026-05-04 | S, sale reported on Form 4 | 4,517 | $1.0M | 2026-05-05 |
| 2026-05-05 | S, sale reported on Form 4 | 233 | $53.2K | 2026-05-05 |
| 2026-09-03 | S, sale reported on Form 4 | 10,000 | $2.1M | 2026-09-03 |
Counted from the Form 4 filings this reporting owner (SEC CIK 1805812) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms